Aimmune Therapeutics, Inc. (NASDAQ:AIMT)‘s stock had its “outperform” rating reaffirmed by analysts at Credit Suisse Group in a note issued to investors on Monday. They presently have a $45.00 price target on the biotechnology company’s stock, up from their previous price target of $36.00. Credit Suisse Group’s price target would indicate a potential upside of 75.37% from the company’s previous close.

Several other analysts have also commented on AIMT. Zacks Investment Research lowered shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Wedbush restated an “outperform” rating and issued a $42.00 price objective on shares of Aimmune Therapeutics in a report on Monday, July 24th. Piper Jaffray Companies set a $38.00 price objective on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a report on Thursday, July 27th. Finally, BidaskClub lowered shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. Aimmune Therapeutics currently has an average rating of “Hold” and a consensus price target of $51.00.

Aimmune Therapeutics (NASDAQ:AIMT) opened at 25.66 on Monday. The company’s 50-day moving average price is $24.75 and its 200-day moving average price is $24.75. The firm’s market capitalization is $1.30 billion. Aimmune Therapeutics has a 1-year low of $14.87 and a 1-year high of $27.31.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.65) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01). Equities research analysts expect that Aimmune Therapeutics will post ($2.71) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Credit Suisse Group Reaffirms “Outperform” Rating for Aimmune Therapeutics, Inc. (AIMT)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/10/23/credit-suisse-group-reaffirms-outperform-rating-for-aimmune-therapeutics-inc-aimt.html.

In other Aimmune Therapeutics news, CEO Stephen George Dilly sold 1,154 shares of the firm’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $26.24, for a total value of $30,280.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Susan E. Barrowcliffe sold 18,390 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $22.00, for a total transaction of $404,580.00. Following the completion of the sale, the insider now owns 3,223 shares of the company’s stock, valued at $70,906. The disclosure for this sale can be found here. Insiders sold 325,000 shares of company stock valued at $7,922,482 over the last 90 days. 24.56% of the stock is currently owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in AIMT. Nationwide Fund Advisors lifted its holdings in shares of Aimmune Therapeutics by 23.7% during the first quarter. Nationwide Fund Advisors now owns 20,095 shares of the biotechnology company’s stock valued at $437,000 after purchasing an additional 3,851 shares during the last quarter. Swiss National Bank lifted its holdings in shares of Aimmune Therapeutics by 17.5% during the first quarter. Swiss National Bank now owns 36,974 shares of the biotechnology company’s stock valued at $803,000 after purchasing an additional 5,500 shares during the last quarter. American International Group Inc. lifted its holdings in shares of Aimmune Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock valued at $352,000 after purchasing an additional 1,070 shares during the last quarter. Teachers Advisors LLC lifted its holdings in shares of Aimmune Therapeutics by 2.6% during the first quarter. Teachers Advisors LLC now owns 44,349 shares of the biotechnology company’s stock valued at $964,000 after purchasing an additional 1,120 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Aimmune Therapeutics by 30.5% during the first quarter. Vanguard Group Inc. now owns 2,199,858 shares of the biotechnology company’s stock valued at $47,803,000 after purchasing an additional 513,803 shares during the last quarter. Hedge funds and other institutional investors own 72.90% of the company’s stock.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Receive News & Stock Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related stocks with our FREE daily email newsletter.